AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca reported (IFRS) R&D expense ($M) ($M)
Form 6-K / 20-F Consolidated Income Statement
Latest, FY2025
-14,232
Period ended Dec 31, 2025
Change on a year earlier
+4.8%
-13,583 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Reported (IFRS) R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -14,232 | +4.8% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | -13,583 | +24.2% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | -10,935 | +12.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -9,762 | +0.3% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | -9,736 | +62.5% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | -5,991 | -198.9% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 6,059 | +2.1% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 5,932 | +3.0% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 5,757 | -2.3% | Form 20-F (filed 2018-03-06) ↗ |
| FY2016 | Dec 31, 2016 | 5,890 | -1.8% | Form 20-F (filed 2018-03-06) ↗ |
| FY2015 | Dec 31, 2015 | 5,997 | – | Form 20-F (filed 2018-03-06) ↗ |
Cite this data
StockData. (2026). AstraZeneca Reported (IFRS) R&D expense ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/rep_rd_cmp
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.